Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poseltinib with Rituximab and Lenalidomide in R/R PCNSL
NCT06737250Phase 2Recruiting
- Sponsor
- NOBO Medicine
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poseltinib in primary central nervous system lymphoma (PCNSL), sponsored by NOBO Medicine. Primary endpoint: Overall Response Rate by IRC at 12 weeks. Started Nov 2024; status: recruiting.
02
Drugs
poseltinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06737250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737250.